risperidone has been researched along with Anxiety in 33 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "RBP-7000 is a sustained-release formulation of risperidone for the treatment of schizophrenia, designed to be administered by once-monthly subcutaneous injection using the ATRIGEL delivery system." | 9.22 | Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study. ( Fava, M; Fudala, PJ; Heidbreder, C; Henderson, DC; Kouassi, A; Nasser, AF; Twumasi-Ankrah, P, 2016) |
| "On the last-observation-carried forward analysis of repeated measures analysis of variance (ANOVA), risperidone was not more effective than placebo for the CGI-21 Anxiety score or the other anxiety outcome measures." | 9.14 | Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. ( Gonzalez, R; Harnett-Sheehan, K; Janavs, J; Keck, PE; McElroy, SL; Rogers, J; Sheehan, DV; Shivakumar, G; Suppes, T, 2009) |
| "2 years) inpatients with depressive and anxiety disorders who were treated with risperidone (median doses per day 1." | 9.12 | Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia. ( Bares, M; Horacek, J; Kopecek, M; Mohr, P, 2006) |
| "In a 1-year, open-label, international multicentre trial of long-acting risperidone in 615 stable adult patients with schizophrenia, self-rated functioning and well-being were measured every 3 months using the Short Form 36-item questionnaire (SF-36)." | 9.11 | Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. ( Eerdekens, M; Fleischhacker, WW; Kemmler, G; Mehnert, A; Rabinowitz, J, 2005) |
| "Risperidone (RIS) alone was administered to patients with neuroleptic-naïve, first-episode schizophrenia who visited the outpatient clinic of the Department of Psychiatry, Jikei University School of Medicine Hospital between April 1998 and December 2001, and the effectiveness of the drug in alleviating anxiety symptoms was prospectively examined." | 9.10 | [A clinical study of emergent anxiety in neuroleptic-naïve, first-episode schizophrenia patients following treatment with risperidone]. ( Katsu, H; Nakayama, K; Sannomiya, M, 2003) |
| "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia." | 9.08 | A syndrome of increased affect in response to risperidone among patients with schizophrenia. ( Ashleigh, EA; Larsen, PD, 1998) |
| " The aim of the present study was to analyze on a single case basis the relationship between a sudden increase in suicidality, anxiety symptoms, medication dosing and clinician- and patient-rated akathisia." | 6.77 | The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. ( Bauer, M; Doucette, S; Lewitzka, U; Meyer, S; Möller, HJ; Musil, R; Riedel, M; Schennach, R; Seemüller, F, 2012) |
| "Risperidone is an atypical antipsychotic that has been investigated as a treatment for several severe psychiatric disorders in children and adults." | 5.30 | Separation anxiety in children and adolescents treated with risperidone. ( Fischer, DJ; Fluent, TE; Hanna, GL, 1999) |
| "RBP-7000 is a sustained-release formulation of risperidone for the treatment of schizophrenia, designed to be administered by once-monthly subcutaneous injection using the ATRIGEL delivery system." | 5.22 | Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study. ( Fava, M; Fudala, PJ; Heidbreder, C; Henderson, DC; Kouassi, A; Nasser, AF; Twumasi-Ankrah, P, 2016) |
| "On the last-observation-carried forward analysis of repeated measures analysis of variance (ANOVA), risperidone was not more effective than placebo for the CGI-21 Anxiety score or the other anxiety outcome measures." | 5.14 | Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. ( Gonzalez, R; Harnett-Sheehan, K; Janavs, J; Keck, PE; McElroy, SL; Rogers, J; Sheehan, DV; Shivakumar, G; Suppes, T, 2009) |
| "2 years) inpatients with depressive and anxiety disorders who were treated with risperidone (median doses per day 1." | 5.12 | Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia. ( Bares, M; Horacek, J; Kopecek, M; Mohr, P, 2006) |
| "In a 1-year, open-label, international multicentre trial of long-acting risperidone in 615 stable adult patients with schizophrenia, self-rated functioning and well-being were measured every 3 months using the Short Form 36-item questionnaire (SF-36)." | 5.11 | Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. ( Eerdekens, M; Fleischhacker, WW; Kemmler, G; Mehnert, A; Rabinowitz, J, 2005) |
| "Risperidone (RIS) alone was administered to patients with neuroleptic-naïve, first-episode schizophrenia who visited the outpatient clinic of the Department of Psychiatry, Jikei University School of Medicine Hospital between April 1998 and December 2001, and the effectiveness of the drug in alleviating anxiety symptoms was prospectively examined." | 5.10 | [A clinical study of emergent anxiety in neuroleptic-naïve, first-episode schizophrenia patients following treatment with risperidone]. ( Katsu, H; Nakayama, K; Sannomiya, M, 2003) |
| "The subjects were 62 patients hospitalized for acute exacerbations of schizophrenia and were randomly assigned to receive risperidone (mean dose, 7." | 5.08 | Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. ( Azorin, JM; Blin, O; Bouhours, P, 1996) |
| "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia." | 5.08 | A syndrome of increased affect in response to risperidone among patients with schizophrenia. ( Ashleigh, EA; Larsen, PD, 1998) |
| "Several clinical reports have documented a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants, in particular selective serotonin reuptake inhibitors (SSRI), in the treatment of drug-resistant depression and treatment-resistant anxiety disorders." | 3.83 | The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats. ( Kaminska, K; Rogoz, Z, 2016) |
| "In the present study was examined the effect of treatment with olanzapine or risperidone, given separately or in combination with fluoxetine, in the elevated plus-maze test (an animal model of anxiety) in male Wistar rats." | 3.77 | Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats. ( Rogóż, Z; Skuza, G, 2011) |
| "We report a case of Sydenham's chorea with neuropsychiatric symptoms who was successfully treated with low-dose risperidone." | 3.75 | Blood levels of catecholamine metabolites and brain-derived neurotrophic factor in a case of Sydenham's chorea. ( Hori, H; Korogi, Y; Nakamura, J; Nakano, H; Shimono, M; Shiota, N; Sugita, A; Takano, K; Tomoda, Y; Umene, W; Yoshimura, R, 2009) |
| " The aim of the present study was to analyze on a single case basis the relationship between a sudden increase in suicidality, anxiety symptoms, medication dosing and clinician- and patient-rated akathisia." | 2.77 | The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. ( Bauer, M; Doucette, S; Lewitzka, U; Meyer, S; Möller, HJ; Musil, R; Riedel, M; Schennach, R; Seemüller, F, 2012) |
| "Preschool children tolerated low-dose risperidone well with no serious adverse effects observed over a 6-month treatment period." | 2.72 | Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. ( Belden, A; Heffelfinger, A; Luby, J; Mrakotsky, C; Spitznagel, E; Stalets, MM; Williams, M, 2006) |
| "The condition has been referred to as Morgellons disease." | 1.48 | Morgellons disease: experiences of an integrated multidisciplinary dermatology team to achieve positive outcomes. ( Bewley, A; Mohandas, P; Taylor, R, 2018) |
| "Risperidone treatment reduced anxiety but increased heart rate." | 1.34 | Blood pressure, heart rate, and anxiety in schizophrenia. ( Baier, MB; Becker, JE; Ritchie, MA; Townsend, MH, 2007) |
| "This report shows symptomatic recurrences persisting more than 8 months." | 1.33 | Hallucinogen persisting perception disorder after psilocybin consumption: a case study. ( Abadie, P; Dollfus, S; Espiard, ML; Halbecq, I; Lecardeur, L, 2005) |
| "An open-label study evaluated the effect of steady-state venlafaxine on the single-dose pharmacokinetic profile of risperidone, a CYP2D6 substrate; its active metabolite, 9-hydroxyrisperidone; and the total active moiety (risperidone plus 9-hydroxyrisperidone)." | 1.30 | Effect of venlafaxine on the pharmacokinetics of risperidone. ( Albano, D; Amchin, J; Klockowski, PM; Taylor, KP; Zarycranski, W, 1999) |
| "Risperidone is an atypical antipsychotic that has been investigated as a treatment for several severe psychiatric disorders in children and adults." | 1.30 | Separation anxiety in children and adolescents treated with risperidone. ( Fischer, DJ; Fluent, TE; Hanna, GL, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (21.21) | 18.2507 |
| 2000's | 12 (36.36) | 29.6817 |
| 2010's | 13 (39.39) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Teixeira, AE | 1 |
| Rocha-Gomes, A | 1 |
| Pereira Dos Santos, T | 1 |
| Amaral, BLS | 1 |
| da Silva, AA | 1 |
| Malagutti, AR | 1 |
| Leite, FRF | 1 |
| Stuckert-Seixas, SR | 1 |
| Riul, TR | 1 |
| Mohandas, P | 1 |
| Bewley, A | 1 |
| Taylor, R | 1 |
| Robinson, DG | 1 |
| Gallego, JA | 1 |
| John, M | 1 |
| Hanna, LA | 1 |
| Zhang, JP | 1 |
| Birnbaum, ML | 1 |
| Greenberg, J | 1 |
| Naraine, M | 1 |
| Peters, BD | 1 |
| McNamara, RK | 1 |
| Malhotra, AK | 1 |
| Szeszko, PR | 1 |
| Torres-Lista, V | 1 |
| López-Pousa, S | 1 |
| Giménez-Llort, L | 1 |
| De Santis, M | 1 |
| Lian, J | 1 |
| Huang, XF | 1 |
| Deng, C | 1 |
| Nasser, AF | 1 |
| Henderson, DC | 1 |
| Fava, M | 1 |
| Fudala, PJ | 1 |
| Twumasi-Ankrah, P | 1 |
| Kouassi, A | 1 |
| Heidbreder, C | 1 |
| Partyka, A | 1 |
| Wasik, A | 1 |
| Jastrzębska-Więsek, M | 1 |
| Mierzejewski, P | 1 |
| Bieńkowski, P | 1 |
| Kołaczkowski, M | 1 |
| Wesołowska, A | 1 |
| Kaminska, K | 1 |
| Rogoz, Z | 2 |
| Sheehan, DV | 1 |
| McElroy, SL | 1 |
| Harnett-Sheehan, K | 1 |
| Keck, PE | 1 |
| Janavs, J | 1 |
| Rogers, J | 1 |
| Gonzalez, R | 1 |
| Shivakumar, G | 1 |
| Suppes, T | 1 |
| Yasui-Furukori, N | 1 |
| Saito, M | 1 |
| Nakagami, T | 1 |
| Furukori, H | 1 |
| Suzuki, A | 1 |
| Kondo, T | 1 |
| Kaneko, S | 1 |
| Ortega-Alvaro, A | 1 |
| Aracil-Fernández, A | 1 |
| García-Gutiérrez, MS | 1 |
| Navarrete, F | 1 |
| Manzanares, J | 1 |
| Rickards, H | 1 |
| Cavanna, AE | 1 |
| Worrall, R | 1 |
| Skuza, G | 1 |
| Seemüller, F | 1 |
| Lewitzka, U | 1 |
| Bauer, M | 1 |
| Meyer, S | 1 |
| Musil, R | 1 |
| Schennach, R | 1 |
| Riedel, M | 1 |
| Doucette, S | 1 |
| Möller, HJ | 1 |
| Gadit, A | 1 |
| Sannomiya, M | 1 |
| Katsu, H | 1 |
| Nakayama, K | 1 |
| Moríñigo, A | 1 |
| Blanco, M | 1 |
| Labrador, J | 1 |
| Martín, J | 1 |
| Noval, D | 1 |
| Kuroki, T | 1 |
| Kaminiwa, S | 1 |
| Haeno, M | 1 |
| Kohara, K | 1 |
| Ninomiya, H | 1 |
| Espiard, ML | 1 |
| Lecardeur, L | 1 |
| Abadie, P | 1 |
| Halbecq, I | 1 |
| Dollfus, S | 1 |
| Fleischhacker, WW | 1 |
| Rabinowitz, J | 1 |
| Kemmler, G | 1 |
| Eerdekens, M | 1 |
| Mehnert, A | 1 |
| Luby, J | 1 |
| Mrakotsky, C | 1 |
| Stalets, MM | 1 |
| Belden, A | 1 |
| Heffelfinger, A | 1 |
| Williams, M | 1 |
| Spitznagel, E | 1 |
| Kopecek, M | 1 |
| Bares, M | 1 |
| Horacek, J | 1 |
| Mohr, P | 1 |
| Townsend, MH | 1 |
| Baier, MB | 1 |
| Becker, JE | 1 |
| Ritchie, MA | 1 |
| Sukhodolsky, DG | 1 |
| Scahill, L | 1 |
| Gadow, KD | 1 |
| Arnold, LE | 1 |
| Aman, MG | 1 |
| McDougle, CJ | 1 |
| McCracken, JT | 1 |
| Tierney, E | 1 |
| Williams White, S | 1 |
| Lecavalier, L | 1 |
| Vitiello, B | 1 |
| Umene, W | 1 |
| Yoshimura, R | 1 |
| Hori, H | 1 |
| Nakano, H | 1 |
| Sugita, A | 1 |
| Shimono, M | 1 |
| Takano, K | 1 |
| Shiota, N | 1 |
| Tomoda, Y | 1 |
| Korogi, Y | 1 |
| Nakamura, J | 1 |
| Jano, E | 1 |
| Johnson, M | 1 |
| Chen, H | 1 |
| Aparasu, RR | 1 |
| Byerly, MJ | 1 |
| Greer, RA | 1 |
| Evans, DL | 1 |
| Blin, O | 1 |
| Azorin, JM | 1 |
| Bouhours, P | 1 |
| Ashleigh, EA | 1 |
| Larsen, PD | 1 |
| Yee, CM | 1 |
| Nuechterlein, KH | 1 |
| Morris, SE | 1 |
| White, PM | 1 |
| Amchin, J | 1 |
| Zarycranski, W | 1 |
| Taylor, KP | 1 |
| Albano, D | 1 |
| Klockowski, PM | 1 |
| Hanna, GL | 1 |
| Fluent, TE | 1 |
| Fischer, DJ | 1 |
| Hori, M | 1 |
| Shiraishi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Detecting Which Patients With Schizophrenia Will Improve With Omega-3 Treatment[NCT01786239] | 50 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder[NCT00277654] | Phase 3 | 111 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders[NCT00025779] | 60 participants | Interventional | 2001-10-31 | Completed | |||
| Neural Mechanisms of CBT for Anxiety in Children With Autism: Randomized Controlled Trial[NCT02725619] | 70 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| Neural Mechanisms of Cognitive-Behavioral Therapy for Anxiety in Children With Autism Spectrum Disorder: A Pilot Study[NCT02225808] | 10 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome measure will be the total Brief Psychiatric Rating Scale Score. The range of the BPRS is 0 to 126 with higher scores indicated more psychological symptoms. (NCT01786239)
Timeframe: 16 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Baseline BPRS Score | Week 16 BPRS Score | |
| Omega-3 Capsules & Risperidone | 41.64 | 22.5868 |
| Placebo & Risperidone | 42.38 | 27.2235 |
1 review available for risperidone and Anxiety
| Article | Year |
|---|---|
[Therapeutic and pharmacological effects of second-generation antipsychotics on drug-resistant bipolar depression].
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety; Benzodiazepines; Bip | 2004 |
11 trials available for risperidone and Anxiety
| Article | Year |
|---|---|
A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Anxiety; Bipolar Disorder; Brief Psychiatric Rating Scale; | 2019 |
Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Delayed-Action Preparations; Double-Blind Me | 2016 |
Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anxiety; Anxiety Disorders; Bipolar Disorder; Comorbi | 2009 |
The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone.
Topics: Adolescent; Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Female; Halo | 2012 |
[A clinical study of emergent anxiety in neuroleptic-naïve, first-episode schizophrenia patients following treatment with risperidone].
Topics: Adult; Age Factors; Antipsychotic Agents; Anxiety; Humans; Male; Prospective Studies; Risperidone; S | 2003 |
Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Anxiety; Dep | 2005 |
Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy.
Topics: Antipsychotic Agents; Anxiety; Autistic Disorder; Behavior Therapy; Child Behavior Disorders; Child, | 2006 |
Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Anxiety; Benzodiazepines; D | 2006 |
Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Double-Blind Method; Drug The | 1996 |
A syndrome of increased affect in response to risperidone among patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Anxiety; Disease Susceptibility; Follow-Up Studies; Humans; Male; Middl | 1998 |
P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Anxiety; Attention; Cognition; Depression; Evoked | 1998 |
21 other studies available for risperidone and Anxiety
| Article | Year |
|---|---|
Cafeteria diet administered from lactation to adulthood promotes a change in risperidone sensitivity on anxiety, locomotion, memory, and social interaction of Wistar rats.
Topics: Animals; Anxiety; Diet; Female; Lactation; Locomotion; Male; Rats; Rats, Wistar; Risperidone; Social | 2020 |
Morgellons disease: experiences of an integrated multidisciplinary dermatology team to achieve positive outcomes.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Local; Antipsychotic | 2018 |
Marble-burying is enhanced in 3xTg-AD mice, can be reversed by risperidone and it is modulable by handling.
Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Anxiety; Behavior, Animal; Disease Models, Animal; | 2015 |
Early antipsychotic treatment in childhood/adolescent period has long-term effects on depressive-like, anxiety-like and locomotor behaviours in adult rats.
Topics: Age Factors; Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines | 2016 |
ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines; Conditioning | 2016 |
The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Anxiety; Behavior, Animal; Cit | 2016 |
Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Anxiety; Cognition; Data Interpretation, Statistical; Depression; | 2010 |
Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antipsychotic Agents; Anxiety; Avoidance Learni | 2011 |
Treatment practices in Tourette syndrome: the European perspective.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Atomoxetine Hydrochloride | 2012 |
Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Drug Interactions; Drug Therapy, Combination | 2011 |
Risperidone associated tardive dyskinesia--a less common phenomenon.
Topics: Anxiety; Depression; Humans; Male; Middle Aged; Movement Disorders; Risperidone; Serotonin Antagonis | 2011 |
Risperidone for resistant anxiety in elderly persons.
Topics: Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Cognition Disorders; Dr | 2005 |
Hallucinogen persisting perception disorder after psilocybin consumption: a case study.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Anxiety; Depressive Disorder; Diagnosis, Di | 2005 |
Blood pressure, heart rate, and anxiety in schizophrenia.
Topics: Adult; Antipsychotic Agents; Anxiety; Blood Pressure; Female; Heart Rate; Humans; Male; Middle Aged; | 2007 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Blood levels of catecholamine metabolites and brain-derived neurotrophic factor in a case of Sydenham's chorea.
Topics: Adolescent; Antipsychotic Agents; Anxiety; Basal Ganglia; Brain-Derived Neurotrophic Factor; Catecho | 2009 |
Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Anxiety; Benzodiazepines; Cross-Sectiona | 2008 |
Behavioral stimulation associated with risperidone initiation.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Benzodiazepines; Confusion; Female; Humans; | 1995 |
Effect of venlafaxine on the pharmacokinetics of risperidone.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety; Area Under Curve; Cy | 1999 |
Separation anxiety in children and adolescents treated with risperidone.
Topics: Adolescent; Antipsychotic Agents; Anxiety; Child; Humans; Male; Obsessive-Compulsive Disorder; Rispe | 1999 |
Risperidone-induced anxiety might also develop 'awakening' phenomenon.
Topics: Adult; Antipsychotic Agents; Anxiety; Humans; Male; Risperidone; Schizophrenia, Paranoid; Sleep Wake | 1999 |